Drugmaker Merck to buy rare disease medicine maker SpringWorks for $3.9 billion
MLex Summary: Global medicine manufacturer Merck, which sells a variety of blockbuster drugs for humans and animals, intends to acquire specialized drugmaker SpringWorks Therapeutics, which focuses on developing treatments for cancers...To view the full article, register now.
Already a subscriber? Click here to view full article